mrc

Novel small molecule inhibitors of PfCDPK1, a novel, validated malarial kinase target. The lead compounds show low nanomolar potency in enzyme and parasite growth assays with good kinase selectivity profiles and ADMET properties. Preliminary data indicate efficacy in vivo. A set of relevant in vitro and cell-based assays are also available. Opportunity 327

Landmark research by a Medical Research Council scientist who has discovered an intracellular immune system whereby antibodies can fight viruses from within infected cells. These findings represent an entirely new system of broad-spectrum immunity which may be exploited for the development of new anti-virals. Opportunity 375

This opportunity covers use of recombinant MSP1 and fragments for the development of malaria vaccines and diagnostic tests for detection of the malaria parasite in blood. Opportunity 256

A novel mouse model of inducible bacterial infection of the middle ear (otitis media) for preclinical testing. The Junbo mouse is specifically predisposed to otitis media and the middle ear can be efficiently infected with human otopathogens by intranasal challenge. The model is suitable for high throughput antibiotic and vaccine research. Opportunity 483